Trials
3 active
3 in total
Targets
—
None known yet
What this is
- How it works
- MET inhibitor unconfirmed
- How it’s given
- “ASKC202 orally once per day (QD) combined with Limertinib orally BID for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.”In the company’s words, NCT07109531 on ClinicalTrials.gov
- Tested for
- Locally Advanced or Metastatic NSCLC, EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive, Advanced Solid Tumor
- Main trialPhase 3
- “This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease progression on EGFR tyrosine kinase inhibitor.”In the company’s words, NCT07109531 on ClinicalTrials.gov
Coming up3
- DecPhase 1 trial completes · ClinicalTrials.gov
- 31 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Dec 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Oct 2027 | ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy | |
| Phase 3Not yet recruiting | 30 Dec 2030 | ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | |
| Phase 1Recruiting | Dec 2026 | Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026